Literature DB >> 9257764

Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp.

J E Sjøstrøm1, T Kühler, H Larsson.   

Abstract

Proton pump inhibitors of the benzimidazole type exert a specific antibacterial activity against Helicobacter pylori in vitro. In the present study, the basis for this selectivity was investigated, and in particular, various factors affecting the in vitro antibacterial activity of sulfide analogs of benzimidazoles were studied. Upon preincubation of omeprazole for a period of up to 72 h in a buffer at pH 7, a product was formed that was bactericidal for H. pylori but had no effect on urease activity. Sulfide constitutes the main end product of degradation. The sulfide analog of omeprazole (H 168/22) exerted a bactericidal activity specifically against both resting (in buffer) and growing (in broth) Helicobacter spp., and time-kill in buffer at pH 5 was enhanced compared to that at pH 7. There was no or very low covalent binding of 3H-labeled H 168/22 to Helicobacter spp. or to other gram-negative and gram-positive bacteria. In the presence of fetal calf serum (FCS) under the same conditions, binding was only slightly lowered while the killing activity was markedly reduced, indicating a probably nonspecific interaction with proteins and/or protection of bacterial target(s) by FCS. Addition of H 168/22 (four times the minimum bactericidal concentration [MBC]) to exponentially growing H. pylori immediately stopped growth, and after an incubation period of 20 h viable counts were reduced by >7 log10. One-hour exposure of H. pylori to the drug followed by repeated washing retarded growth by about 2 h, indicating that the effect is reversible after short-term exposure. MICs and MBCs of various sulfide structures were lower than those obtained in broth after the addition of the corresponding sulfoxide. Thus, the MBC of the sulfide structure of omeprazole against 140 clinical isolates of H. pylori ranged from 8 to 32 microg/ml, compared to an MBC of omeprazole of 32 to 128 microg/ml. A similar potency was also recorded against other helicobacters. In conclusion, formation of sulfides of benzimidazoles in culture media is the reason for the selective antibacterial effect against H. pylori. The sulfides rapidly exerted a reversible antibacterial activity, which was specific against both resting and growing Helicobacter spp. without any covalent protein binding.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9257764      PMCID: PMC164008     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.

Authors:  T Iwahi; H Satoh; M Nakao; T Iwasaki; T Yamazaki; K Kubo; T Tamura; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori.

Authors:  S Suerbaum; H Leying; K Klemm; W Opferkuch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

3.  Phylogeny of Helicobacter felis sp. nov., Helicobacter mustelae, and related bacteria.

Authors:  B J Paster; A Lee; J G Fox; F E Dewhirst; L A Tordoff; G J Fraser; J L O'Rourke; N S Taylor; R Ferrero
Journal:  Int J Syst Bacteriol       Date:  1991-01

4.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.

Authors:  E Fellenius; T Berglindh; G Sachs; L Olbe; B Elander; S E Sjöstrand; B Wallmark
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

5.  Structure-activity relationship of omeprazole and analogues as Helicobacter pylori urease inhibitors.

Authors:  T C Kühler; J Fryklund; N A Bergman; J Weilitz; A Lee; H Larsson
Journal:  J Med Chem       Date:  1995-12-08       Impact factor: 7.446

6.  Isolation of a spiral-shaped bacterium from the cat stomach.

Authors:  A Lee; S L Hazell; J O'Rourke; S Kouprach
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

7.  Compositional analysis of Helicobacter pylori rough-form lipopolysaccharides.

Authors:  A P Moran; I M Helander; T U Kosunen
Journal:  J Bacteriol       Date:  1992-02       Impact factor: 3.490

8.  Steryl glycosides: a characteristic feature of the Helicobacter spp.?

Authors:  M Haque; Y Hirai; K Yokota; K Oguma
Journal:  J Bacteriol       Date:  1995-09       Impact factor: 3.490

9.  Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant.

Authors:  J E Sjöström; H Larsson
Journal:  J Med Microbiol       Date:  1996-06       Impact factor: 2.472

10.  Partial characterization and effect of omeprazole on ATPase activity in Helicobacter pylori by using permeabilized cells.

Authors:  W A Belli; J Fryklund
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  10 in total

1.  Inhibition of biofilm formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  Vandana Singh; Vaneet Arora; M Jahangir Alam; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Real-world Helicobacter pylori diagnosis in patients referred for esophagoduodenoscopy: The gap between guidelines and clinical practice.

Authors:  Dor Shirin; Shay Matalon; Benjamin Avidan; Efrat Broide; Haim Shirin
Journal:  United European Gastroenterol J       Date:  2016-01-08       Impact factor: 4.623

3.  Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan.

Authors:  Tsutomu Nishida; Masahiko Tsujii; Hirohisa Tanimura; Shusaku Tsutsui; Shingo Tsuji; Akira Takeda; Atsuo Inoue; Hiroyuki Fukui; Toshiyuki Yoshio; Osamu Kishida; Hiroyuki Ogawa; Masahide Oshita; Ichizo Kobayashi; Shinichiro Zushi; Makoto Ichiba; Naoto Uenoyama; Yuichi Yasunaga; Ryu Ishihara; Mamoru Yura; Masato Komori; Satoshi Egawa; Hideki Iijima; Tetsuo Takehara
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 4.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options.

Authors:  Ana L Flores-Mireles; Jennifer N Walker; Michael Caparon; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2015-04-08       Impact factor: 60.633

5.  A Chemical Genetics Screen Reveals Influence of p38 Mitogen-Activated Protein Kinase and Autophagy on Phagosome Development and Intracellular Replication of Brucella neotomae in Macrophages.

Authors:  Yoon-Suk Kang; James E Kirby
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

6.  Antiinfectives targeting enzymes and the proton motive force.

Authors:  Xinxin Feng; Wei Zhu; Lici A Schurig-Briccio; Steffen Lindert; Carolyn Shoen; Reese Hitchings; Jikun Li; Yang Wang; Noman Baig; Tianhui Zhou; Boo Kyung Kim; Dean C Crick; Michael Cynamon; J Andrew McCammon; Robert B Gennis; Eric Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

7.  The Discovery and Development of Thienopyrimidines as Inhibitors of Helicobacter pylori That Act through Inhibition of the Respiratory Complex I.

Authors:  Alex K Mugengana; Nicole A Vita; Autumn Brown Gandt; Kevin Moran; George Agyapong; Lalit K Sharma; Elizabeth C Griffith; Jiuyu Liu; Lei Yang; Ekaterina Gavrish; Kirk E Hevener; Michael D LaFleur; Richard E Lee
Journal:  ACS Infect Dis       Date:  2021-01-20       Impact factor: 5.084

Review 8.  The Possible Role of Helicobacter pylori in Gastric Cancer and Its Management.

Authors:  Khalid O Alfarouk; Adil H H Bashir; Ahmed N Aljarbou; AbdelRahman M Ramadan; Abdel Khalig Muddathir; Sari T S AlHoufie; Abdelhamid Hifny; Gamal O Elhassan; Muntaser E Ibrahim; Saad S Alqahtani; Shakir D AlSharari; Claudiu T Supuran; Cyril Rauch; Rosa Angela Cardone; Stephan J Reshkin; Stefano Fais; Salvador Harguindey
Journal:  Front Oncol       Date:  2019-02-22       Impact factor: 6.244

9.  Binding of omeprazole to protein targets identified by monoclonal antibodies.

Authors:  Naw May Pearl Cartee; Michael M Wang
Journal:  PLoS One       Date:  2020-09-18       Impact factor: 3.240

10.  Lansoprazole Novel Effector Sites Revealed by Autoradiography: Relation to Helicobacter pylori, Colon, Esophagus and Others.

Authors:  Masahiko Nakamura; Hidenori Matsui; Hiroshi Serizawa; Kanji Tsuchimoto
Journal:  J Clin Biochem Nutr       Date:  2007-11       Impact factor: 3.114

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.